Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

1.

Temporal proteomics of NGF-TrkA signaling identifies an inhibitory role for the E3 ligase Cbl-b in neuroblastoma cell differentiation.

Emdal KB, Pedersen AK, Bekker-Jensen DB, Tsafou KP, Horn H, Lindner S, Schulte JH, Eggert A, Jensen LJ, Francavilla C, Olsen JV.

Sci Signal. 2015 Apr 28;8(374):ra40. doi: 10.1126/scisignal.2005769.

PMID:
25921289
2.

Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma: implications for targeted treatment.

Lambertz I, Kumps C, Claeys S, Lindner S, Beckers A, Janssens E, Carter DR, Cazes A, Cheung BB, De Mariano M, De Bondt A, De Brouwer S, Delattre O, Gibbons J, Janoueix-Lerosey I, Laureys G, Liang C, Marshall GM, Porcu M, Takita J, Camacho Trujillo D, Van Den Wyngaert I, Van Roy N, Van Goethem A, Van Maerken T, Zabrocki P, Cools J, Schulte JH, Vialard J, Speleman F, De Preter K.

Clin Cancer Res. 2015 Mar 24. pii: clincanres.2024.2014. [Epub ahead of print]

PMID:
25805801
3.

IGF2BP1 Harbors Prognostic Significance by Gene Gain and Diverse Expression in Neuroblastoma.

Bell JL, Turlapati R, Liu T, Schulte JH, Hüttelmaier S.

J Clin Oncol. 2015 Apr 10;33(11):1285-93. doi: 10.1200/JCO.2014.55.9880. Epub 2015 Mar 9.

PMID:
25753434
4.

Neoadjuvant/adjuvant treatment of high-risk retinoblastoma: a report from the German Retinoblastoma Referral Centre.

Künkele A, Wilm J, Holdt M, Lohmann D, Bornfeld N, Eggert A, Temming P, Schulte JH.

Br J Ophthalmol. 2015 Jan 12. pii: bjophthalmol-2014-306222. doi: 10.1136/bjophthalmol-2014-306222. [Epub ahead of print]

PMID:
25583279
5.

CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients.

Rihani A, De Wilde B, Zeka F, Laureys G, Francotte N, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J, Van Maerken T.

PLoS One. 2014 Dec 11;9(12):e114696. doi: 10.1371/journal.pone.0114696. eCollection 2014.

6.

Neuroblastoma in dialog with its stroma: NTRK1 is a regulator of cellular cross-talk with Schwann cells.

Pajtler KW, Mahlow E, Odersky A, Lindner S, Stephan H, Bendix I, Eggert A, Schramm A, Schulte JH.

Oncotarget. 2014 Nov 30;5(22):11180-92.

7.

ALK pERKs up MYCN in neuroblastoma.

Lindner S, Henssen A, Astrahantseff K, Schulte JH.

Sci Signal. 2014 Oct 28;7(349):pe27. doi: 10.1126/scisignal.2005940.

PMID:
25351246
8.

MiR-34a deficiency accelerates medulloblastoma formation in vivo.

Thor T, Künkele A, Pajtler KW, Wefers AK, Stephan H, Mestdagh P, Heukamp L, Hartmann W, Vandesompele J, Sadowski N, Becker L, Garrett L, Hölter SM, Horsch M, Calzada-Wack J, Klein-Rodewald T, Racz I, Zimmer A, Beckers J, Neff F, Klopstock T, De Antonellis P, Zollo M, Wurst W, Fuchs H, Gailus-Durner V, Schüller U, de Angelis MH, Eggert A, Schramm A, Schulte JH.

Int J Cancer. 2015 May 15;136(10):2293-303. doi: 10.1002/ijc.29294. Epub 2014 Nov 25.

PMID:
25348795
9.

Robust selection of cancer survival signatures from high-throughput genomic data using two-fold subsampling.

Lee S, Rahnenführer J, Lang M, De Preter K, Mestdagh P, Koster J, Versteeg R, Stallings RL, Varesio L, Asgharzadeh S, Schulte JH, Fielitz K, Schwermer M, Morik K, Schramm A.

PLoS One. 2014 Oct 8;9(10):e108818. doi: 10.1371/journal.pone.0108818. eCollection 2014.

10.

MYCN-targeting miRNAs are predominantly downregulated during MYCN‑driven neuroblastoma tumor formation.

Beckers A, Van Peer G, Carter DR, Mets E, Althoff K, Cheung BB, Schulte JH, Mestdagh P, Vandesompele J, Marshall GM, De Preter K, Speleman F.

Oncotarget. 2015 Mar 10;6(7):5204-16.

11.

MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis.

Bleeker G, van Eck-Smit BL, Zwinderman KH, Versteeg R, van Noesel MM, Kam BL, Kaspers GJ, van Schie A, Kreissman SG, Yanik G, Hero B, Schmidt M, Laureys G, Lambert B, Øra I, Schulte JH, Caron HN, Tytgat GA.

Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):222-30. doi: 10.1007/s00259-014-2909-1. Epub 2014 Sep 30.

12.

A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.

Althoff K, Beckers A, Bell E, Nortmeyer M, Thor T, Sprüssel A, Lindner S, De Preter K, Florin A, Heukamp LC, Klein-Hitpass L, Astrahantseff K, Kumps C, Speleman F, Eggert A, Westermann F, Schramm A, Schulte JH.

Oncogene. 2014 Sep 1. doi: 10.1038/onc.2014.269. [Epub ahead of print]

PMID:
25174395
13.

p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.

Dreidax D, Bannert S, Henrich KO, Schröder C, Bender S, Oakes CC, Lindner S, Schulte JH, Duffy D, Schwarzl T, Saadati M, Ehemann V, Benner A, Pfister S, Fischer M, Westermann F.

Hum Mol Genet. 2014 Dec 20;23(25):6826-37. doi: 10.1093/hmg/ddu406. Epub 2014 Aug 7.

PMID:
25104850
14.

miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin.

Althoff K, Lindner S, Odersky A, Mestdagh P, Beckers A, Karczewski S, Molenaar JJ, Bohrer A, Knauer S, Speleman F, Epple M, Kozlova D, Yoon S, Baek K, Vandesompele J, Eggert A, Schramm A, Schulte JH.

Int J Cancer. 2015 Mar 15;136(6):1308-20. doi: 10.1002/ijc.29091. Epub 2014 Aug 5.

PMID:
25046253
15.

Early targets of miR-34a in neuroblastoma.

De Antonellis P, Carotenuto M, Vandenbussche J, De Vita G, Ferrucci V, Medaglia C, Boffa I, Galiero A, Di Somma S, Magliulo D, Aiese N, Alonzi A, Spano D, Liguori L, Chiarolla C, Verrico A, Schulte JH, Mestdagh P, Vandesompele J, Gevaert K, Zollo M.

Mol Cell Proteomics. 2014 Aug;13(8):2114-31. doi: 10.1074/mcp.M113.035808. Epub 2014 Jun 9.

PMID:
24912852
16.

Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.

Rihani A, Van Maerken T, De Wilde B, Zeka F, Laureys G, Norga K, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J.

Pediatr Blood Cancer. 2014 Oct;61(10):1867-70. doi: 10.1002/pbc.24927. Epub 2014 Jan 4.

PMID:
24391119
17.

The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma.

Pajtler KW, Weingarten C, Thor T, Künkele A, Heukamp LC, Büttner R, Suzuki T, Miyata N, Grotzer M, Rieb A, Sprüssel A, Eggert A, Schramm A, Schulte JH.

Acta Neuropathol Commun. 2013 May 29;1(1):19. doi: 10.1186/2051-5960-1-19.

18.

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.

Henssen A, Thor T, Odersky A, Heukamp L, El-Hindy N, Beckers A, Speleman F, Althoff K, Schäfers S, Schramm A, Sure U, Fleischhack G, Eggert A, Schulte JH.

Oncotarget. 2013 Nov;4(11):2080-95.

19.

Targeted Therapy for Neuroblastoma: ALK Inhibitors.

Schulte JH, Schulte S, Heukamp LC, Astrahantseff K, Stephan H, Fischer M, Schramm A, Eggert A.

Klin Padiatr. 2013 Nov;225(6):303-8. doi: 10.1055/s-0033-1357132. Epub 2013 Oct 28. Review.

PMID:
24166094
20.

The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia.

Künkele A, Grosse-Lordemann A, Schramm A, Eggert A, Schulte JH, Bachmann HS.

BMC Cancer. 2013 Oct 2;13:452. doi: 10.1186/1471-2407-13-452.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk